Movement Alert|Teradyne Pre-Market Rise 8.69%, Q2 Earnings and Q3 Guidance Significantly Beat Expectations

Market Focus
Jul 29

On July 29, Teradyne rose 8.69% in pre-market trading, trading at 347.07 USD/share, with turnover of 1.4826 million USD.

The surge was driven by the company's Q2 earnings report released after the prior session's close, which significantly exceeded market expectations. Q2 adjusted EPS came in at $2.47, beating the analyst consensus of $2.09 by 18%. Revenue reached $1.33 billion, up 104% year-over-year from $652 million, surpassing the $1.22 billion estimate. Semiconductor test revenue contributed $1.122 billion as the core growth engine.

Q3 guidance was equally strong, with projected adjusted EPS of $1.85 to $2.15 (midpoint $2.00), far exceeding the Street consensus of $1.44, and revenue guidance of $1.2 billion to $1.3 billion, well above the $1.06 billion estimate. The stock had declined nearly 7% during regular trading on July 28 amid broad semiconductor equipment sector selling pressure, but reversed sharply following the earnings beat. Multiple Wall Street firms including UBS, JPMorgan, and Goldman Sachs have recently raised price targets to the $450-$500 range.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10